The Medicines Company (MDCO) - Financial and Strategic SWOT Analysis Review

Date: June 13, 2018
Pages: 54
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MA75ED5ECA2EN
Leaflet:

Download PDF Leaflet

The Medicines Company (MDCO) - Financial and Strategic SWOT Analysis Review
The Medicines Company (MDCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle-free patient-controlled system for short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital. Its pipeline products include an investigational anesthetic agent; and an investigational lipid-lowering drug. TMC also provides acute care generic pharmaceuticals products. The company offers its products for major therapeutic areas, which include surgery and perioperative care, acute care, and cardiovascular care. It has offices and other facilities in the US, the UK, Canada and other European countries. TMC is headquartered in Parsippany, New Jersey, the US.

The Medicines Company Key Recent Developments

May 07,2018: OU-Led Research Team Accelerating Antibiotic Discovery
Apr 25,2018: The Medicines Company Reports First-Quarter 2018 Results
Mar 27,2018: The Medicines Company Announces Chief Financial Officer Transition
Feb 27,2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors
Feb 21,2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

The Medicines Company - Key Facts
The Medicines Company - Key Employees
The Medicines Company - Key Employee Biographies
The Medicines Company - Major Products and Services
The Medicines Company - History
The Medicines Company - Company Statement
The Medicines Company - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

The Medicines Company - Business Description
R&D Overview
The Medicines Company - Corporate Strategy
The Medicines Company - SWOT Analysis
SWOT Analysis - Overview
The Medicines Company - Strengths
The Medicines Company - Weaknesses
The Medicines Company - Opportunities
The Medicines Company - Threats
The Medicines Company - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
The Medicines Company, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 07, 2018: OU-Led Research Team Accelerating Antibiotic Discovery
Apr 25, 2018: The Medicines Company Reports First-Quarter 2018 Results
Mar 27, 2018: The Medicines Company Announces Chief Financial Officer Transition
Feb 27, 2018: The Medicines Company Appoints Dr. Sarah Schlesinger to Its Board of Directors
Feb 21, 2018: The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results
Nov 15, 2017: The Medicines Company Names Dr. Fred Eshelman as Executive Chairman; Appoints Geno Germano to Its Board of Directors
Oct 25, 2017: The Medicines Company Reports Third-Quarter 2017 Business and Financial Results
Aug 09, 2017: The Medicines Company Reports Second Quarter 2017 Business and Financial Results
Apr 26, 2017: The Medicines Company Reports First-Quarter 2017 Financial Results
Mar 31, 2017: The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

The Medicines Company, Key Facts
The Medicines Company, Key Employees
The Medicines Company, Key Employee Biographies
The Medicines Company, Major Products and Services
The Medicines Company, History
The Medicines Company, Subsidiaries
The Medicines Company, Key Competitors
The Medicines Company, Ratios based on current share price
The Medicines Company, Annual Ratios
The Medicines Company, Annual Ratios (Cont.1)
The Medicines Company, Annual Ratios (Cont.2)
The Medicines Company, Interim Ratios
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
The Medicines Company, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

The Medicines Company, Performance Chart (2013 - 2017)
The Medicines Company, Ratio Charts
The Medicines Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
The Medicines Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

COMPANIES MENTIONED

Monarch Pharmaceuticals, Inc.
Merck & Co Inc
Medicure Inc
Johnson & Johnson
Iroko Pharmaceuticals LLC
ImmunoBiosciences Inc
Eli Lilly and Co
Cubist Pharmaceuticals LLC
Skip to top


Ask Your Question

The Medicines Company (MDCO) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: